SCHEMBL22402969

SCHEMBL22402969

COC(=O)Nc1ccc(C[C@@H](O)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.59
RAB9A P51151 2/20 0.59
NPC1 O15118 1/20 0.59
POLB P06746 1/20 0.50
HPGD P15428 1/20 0.48
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
KDM1A O60341 2/20 0.46
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
HDAC8 Q9BY41 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
ROCK2 O75116 1/20 0.45
LTA4H P09960 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
CTRB1 P17538 2/20 0.45
MGLL Q99685 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
F2 P00734 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552129 1.00 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1POLBHPGD
SCHEMBL7217491 0.90 POLB (0.57) SMN1; SMN2RAB9ANPC1POLBTP53
SCHEMBL28476992 0.84 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1POLBHPGD
SCHEMBL7217283 0.84 POLB (0.59) SMN1; SMN2RAB9ANPC1POLBTP53
SCHEMBL7046944 0.83 ALDH1A1 (0.55) KMT2ALTA4HCTRB1ALDH1A1
SCHEMBL262278 0.83 ALDH1A1 (0.55) KMT2ALTA4HCTRB1ALDH1A1
SCHEMBL4219709 0.83 ALDH1A1 (0.55) KMT2ALTA4HCTRB1ALDH1A1
SCHEMBL8741875 0.82 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1POLBHPGD
SCHEMBL3901283 0.82 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1POLBHPGD
SCHEMBL8366738 0.82 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790876-B1 ENDOPARASITIC DEPSIPEPTIDES ZOETIS SERVICES LLC (US) 2025-04-30 EP disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
US-20220323540-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2022-10-13 US disclosed
US-20220211802-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2022-07-07 US disclosed
US-20220211802-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2022-07-07 US disclosed
US-11331369-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2022-05-17 US disclosed
US-11331369-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2022-05-17 US disclosed
US-20200282016-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2020-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786575-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-20200282016-A1 Endoparasitic Depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-20220211802-A1 Endoparasitic Depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 SMN1; SMN2 3783/4885RAB9A 901/4885NPC1 1035/4885
US-20220323540-A1 Endoparasitic Depsipeptides VIP, PREP, VIPR1 SMN1; SMN2 3783/4885RAB9A 901/4885NPC1 1035/4885
US-11331369-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.